New use of hemin and compound thereof to medicines

Abstract

The invention provides an application of hemin and / or hemin compounds thereof to preparation of medicines for preventing and treating rheumatoid arthritis. The hemin or the hemin compounds have remarkable effect of resisting inflammation when being used for performing in vitro action on macrophages, can effectively restrain vola swelling for a rat arthritis model, and can notably reduce expressionof metapodium inflammatory factor mRNA and mRNA expression of liver and spleen tissue autoimmunity correlation factors. The application explains that the hemin or the hemin compounds have good effectof preventing and treating rheumatoid arthritis.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the new application of hemin and its compound in medicine. Background technique [0002] Hemin (Hemin), also known as hemin or hemin (Haemin or FerricChloride Heme). Hemin is a porphyrin compound containing ferric ions. Hemin can be oxidized from natural heme, the chemical properties of the former and the latter are similar. Heme is ubiquitous in animal blood, muscle and some plant tissues. It is the key prosthetic group of many biologically active macromolecules (such as hemoglobin, muscle protein, cytochrome and peroxidase, etc.), so heme is the key prosthetic group of organisms. One of the most important compounds in [0003] [0004] Hemin CAS No. 16009-13-5, molecular formula C 34 h 32 ClFeN 4 o 4 , the relative molecular mass is 651.94. The chemical structure of hemin is shown above. Since the chemical structural formula of hemin contains a large hydrophob...

AI Technical Summary

Problems solved by technology

[0014] The first category is non-steroidal anti-inflammatory drugs (Non-steroid anti-inflammatory drugs, NSAIDs), by inhibiting cyclooxygenase, inhibiting the transformation of arachidonic acid into prostaglandins, thereby playing the role of anti-inflammatory and analgesic, in the present invention The control drug used in this category is celecoxib (celecoxib), which is a highly selective and reversible COX-2 inhibitor, but this type of drug can only relieve symptoms, and cannot prevent and alleviate cartilage and bone damage

[0015] The second category is anti-rheumatic drugs (Disease-modifying antirheumatic drugs, DMARDs), which mainly exert a certain anti-RA effect through cytotoxicity and immunosuppression, and can delay but not prevent joint damage. Loss of benefit over time

[0016] The third category is glucocorticoids, which have powerful anti-inflammatory effects, but have a short half-life, are massively metabolized in the body, and have a series of side effects such as excessive immunosuppression, osteoporosis, and even osteonecrosis. For the treatment of rheumatoid arthritis, which itself has bone and joint pathological changes, its side effects on the body's bones are particularly unfavorable

However, compared with traditional DMARDS, these drugs are very expensive, which limits their clinical application and has certain side effects, including serious and opportunistic infections.

Images